Daily glucocorticoid treatment has an impact on height and weight in patients (pts) with DMD. The objective of this analysis is to compare the effect of prednisone (PDN), deflazacort (DFZ) and vamorolone (VAM) on height and body mass index (BMI) in DMD pts aged 4 to <7 years at the start of treatment. Boys treated with PDN 0.75 mg/kg/day(n=55) or daily DFZ 0.9 mg/kg/day (n=49) from the FOR-DMD study were compared to pts treated with VAM 2.0 (n=28) or 6.0 mg/kg/day (n=28) in the VISION-DMD study (up to 48-weeks) or treated with 2-6 mg/kg/d flexible dosing in the VBP15-LTE study (n= 46) (up to 2.5 years). Height and BMI z-scores were calculated using the CDC growth data and annualized slopes of changes over 1 year (FOR-DMD versus VISION-DMD) and over 2.5 years (FOR-DMD versus VBP15-LTE) were analyzed. At Week 48-52, H z-score decreased -0,30 SDS in the FOR-PDN and -0,50 SDS in the FOR-DFZ group while it increased +0,16 SDS in the VIS-VAM 2 and +0,29 in the VIS-VAM 6 cohorts. After 30 months of treatment. the H z-score decreased -0,69 SDS in the FOR-PDN and -1,0 SDS in the FOR-DFL boys and increased 0,09 SDS in the LTE-VAM patients At Week 48-52 and at 2.5 years, most of the pts (>70%) in all groups had higher BMI z-scores than at baseline. After 2.5 years of treatment, large increases of BMI (>0.5, >0.75 or >1.0 SDS) were seen most frequently in DFZ and PDN groups and the change in BMI z-score was less with VAM than with PDN and DFL when the baseline BMI was taken into account (conditional BMI change analysis). In conclusion, this between study comparisons suggest that daily vamorolone has less effect of height and BMI than daily prednisone or deflazacort.